Characterization of iron oxide nanoparticles adsorbed with cisplatin for biomedical applications

Physics in Medicine and Biology

Volumn 54, Issue 17, 2009, Pages 5109-5121

  Kettering, Melanie ^a   Zorn, Heike ^a   Bremer Streck, Sibylle ^a   Oehring, Hartmut ^a   Zeisberger, Matthias ^b   Bergemann, Christian ^c   Hergt, Rudolf ^b   Halbhuber, Karl Jürgen ^a   Kaiser, Werner A ^a   Hilger, Ingrid ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b LEIBNIZ INSTITUTE OF PHOTONIC TECHNOLOGY   (Germany)

^c Chemicell GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATING MAGNETIC FIELD; BIOLOGICAL MEDIA; BIOMEDICAL APPLICATIONS; CANCER TREATMENT; CHEMOTHERAPEUTIC ACTIVITY; CIS-PLATIN; CORE DIAMETERS; FETAL CALF SERUMS; HYDRODYNAMIC DIAMETER; IN-VITRO; INCUBATION TIME; IRON OXIDE NANOPARTICLE; LASER DIFFRACTIONS; LONG TERM; LOSS POWER; MAGNETIC HEATING; MAGNETIC NANOPARTICLES; MAGNETITE CORES; MAGNETIZATION DATA; MEDICINAL APPLICATIONS; PHOSPHATE-BUFFERED SALINES; SUPERPARAMAGNETICS; THERAPEUTIC EFFECTS; VIBRATING SAMPLE MAGNETOMETRY;

ABSORPTION SPECTROSCOPY; ATOMIC ABSORPTION SPECTROMETRY; BIOLOGICAL ORGANS; DESORPTION; FLUID DYNAMICS; HEATING; HYDRODYNAMICS; IRON ORES; IRON OXIDES; MAGNETIC FIELDS; NANOPARTICLES; OXIDE MINERALS; SUPERPARAMAGNETISM; TRANSMISSION ELECTRON MICROSCOPY; TUMORS;

PLATINUM COMPOUNDS;

CISPLATIN; IRON OXIDE; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; ANTINEOPLASTIC AGENT; DNA; DRUG CARRIER; FERRIC ION; FERRIC OXIDE; STARCH;

ADSORPTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BEHAVIOR; CANCER INVASION; CANCER THERAPY; DRUG STABILITY; FEASIBILITY STUDY; FETAL CALF SERUM; HEATING; HYDRODYNAMICS; HYPERTHERMIA; IN VITRO STUDY; INCUBATION TIME; LASER DIFFRACTION; MAGNETIC FIELD; MAGNETISM; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; HEAT; METABOLISM; PARTICLE SIZE; TIME;

ADSORPTION; ANTINEOPLASTIC AGENTS; CISPLATIN; DNA; DRUG CARRIERS; FERRIC COMPOUNDS; HOT TEMPERATURE; MAGNETICS; NANOPARTICLES; PARTICLE SIZE; STARCH; TIME FACTORS;

EID: 70350488709     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/54/17/003     Document Type: Article

References (43)

1. Alexiou C, Jurgons R, Schmid R J, Bergemann C, Henke J, Erhardt W, Huenges E and Parak F 2003 Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment J. Drug. Target 11 139-49
2. Alexiou C, Schmidt A, Klein R, Hulin P, Bergemann C and Arnold W 2002 Magnetic drug targeting: biodistribution and dependency on magnetic field strength in vitro J. Magn. Magn. Mater. 252 363-6
3. Alexiou C, Schmid R J, Jurgons R, Kremer M, Wanner G, Bergemann C, Huenges E, Nawroth T, Arnold W and Parak F G 2006 Targeting cancer cells: magnetic nanoparticles as drug carriers Eur. Biophys. J. 35 446-50
4. Babincov M, Altanerov V, Altaner C, Bergemann C and Babinec P 2008 In vitro analysis of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and electromagnetic hyperthermia IEEE Trans. Nanobiosci. 7 15-9
5. Barlogie B, Corry P M and Drewinko B 1980 In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C Cancer Res. 40 1165-8 (Pubitemid 10135826)
6. Bergemann C, Müller-Schulte D, Oster J, Brassard L and Lubbe A S 1999 Magnetic ion-exchange nano- and microparticles for medical, biochemical and molecular biological applications J. Magn. Magn. Mater. 194 45-52
7. Berry C C and Curtis A S 2003 Functionalisation of magnetic nanoparticles for applications in biomedicine J. Phys. D: Appl. Phys. 36 R198-R206
8. Bohren C F and Huffman D R 1998 Absorption and Scattering of Light by Small Particles (New York: Wiley)
9. Bulte J W et al 2001 Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells Nat. Biotechnol. 19 1141-7
10. Chantrell R W, Popplewell J and Charles S W 1978 Measurement of particle size distribution parameters in ferrofluids IEEE Trans. Magn. 14 975-7
11. Corot C, Robert P, Idee J M and Port M 2006 Recent advances in iron oxide nanocrystal technology for medical imaging Adv. Drug. Deliv. Rev. 58 1471-504
12. Dressman D, Yan H, Traverso G, Kinzler K W and Vogelstein B 2003 Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations Proc. Natl Acad. Sci. USA 100 8817-22
13. 3 magnetic nanoparticles J. Am. Chem. Soc. 125 1684-5
14. Greene R F, Chatterji D C, Hiranaka P K and Gallelli J F 1979 Stability of cisplatin in aqueous solution Am. J. Hosp. Pharm. 36 38-43
15. Gupta A K and Gupta M 2005 Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications Biomaterials 26 3995-4021
16. Haveman J, Bergs J W, Franken N A, van Bree C and Stalpers L J 2005 Effect of hyperthermia on uptake and cytotoxicity of cisplatin in cultured murine mammary carcinoma cells Oncol. Rep. 14 561-7
17. Hergt R and Andrä W 2006 Magnetic hyperthermia and thermoablation Magnetism in Medicine-A Handbook ed W Andrä and H Nowak (Weinheim: Wiley-VCH)
18. Hergt R, Hiergeist R, Zeisberger M, Glöckl G, Weitschies W, Ramirez L P, Hilger I and Kaiser W A 2004 Enhancement of AC-losses of magnetic nanoparticles for heating applications J. Magn. Magn. Mater. 280 358-68
19. Herman T S, Henle K J, Nagle W A, Moss A J and Monson T P 1984 Effect of step-down heating on the cytotoxicity of adriamycin, bleomycin, and cis-diamminedichloroplatinum Cancer Res. 44 1823-6
20. Hilger I, Hergt R and Kaiser W A 2000 Effects of magnetic thermoablation in muscle tissue using iron oxide particles: an in vitro study Invest. Radiol. 35 170-9
21. Hilger I, Hergt R and Kaiser W A 2005a Use of magnetic nanoparticle heating in the treatment of breast cancer IEE Proc. Nanobiotechnol. 152 33-9
22. Hilger I, Hiergeist R, Hergt R, Winnefeld K, Schubert H and Kaiser W A 2002a Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study Invest. Radiol. 37 580-6
23. Hilger I, Hofmann F, Reichenbach J R, Bergemann C, Hiergeist R, Andra W, Hergt R and Kaiser W A 2002b In vitro imaging of magnetite particles Rofo 174 101-3
24. Hilger I, Rapp A, Greulich K O and Kaiser W A 2005b Assessment of DNA damage in target tumor cells after thermoablation in mice Radiology 237 500-6
25. Ito A, Shinkai M, Honda H and Kobayashi T 2005 Medical application of functionalized magnetic nanoparticles J. Biosci. Bioeng. 100 1-11
26. Jordan A, Scholz R, Wust P, Fahling H, Krause J, Wlodarcyk W, Sander B, Vogel T and Felix R 1997 Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo Int. J. Hyperthermia 13 587-605
27. Kettering M et al 2007 Magnetic nanoparticles as bimodal tools in magnetically induced labelling and magnetic heating of tumour cells: an in vitro study Nanotechnology 18 175101 (9 pp)
28. Lewin M, Carlesso N, Tung C H, Tang X W, Cory D, Scadden D T and Weissleder R 2000 Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells Nat. Biotechnol. 18 410-4
29. Livingston E H 2004 The mean and standard deviation: what does it all mean? J. Surg. Res. 119 117-23
30. Los G, van Vugt M J, den Engelse L and Pinedo H M 1993 Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA Biochem. Pharmacol. 46 1229-37
31. Los G, van Vugt M J and Pinedo H M 1994 Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin Br. J. Cancer 69 235-41
32. Morandi S, Ristori S, Berti D, Panza L, Becciolini A and Martini G 2004 Association of sugar-based carboranes with cationic liposomes: an electron spin resonance and light scattering study Biochim. Biophys. Acta 1664 53-63
33. Plank C, Schillinger U, Scherer F, Bergemann C, Remy J S, Krotz F, Anton M, Lausier J and Rosenecker J 2003 The magnetofection method: using magnetic force to enhance gene delivery Biol. Chem. 384 737-47
34. Raaphorst G P, Li L F, Yang D P and LeBlanc J M 2005 Cisplatin sensitization by concurrent mild hyperthermia in parental and mutant cell lines deficient in homologous recombination and non-homologous endjoining repair Oncol. Rep. 14 281-5
35. Sosnovik D E and Weissleder R 2006 Emerging concepts in molecular MRI Curr. Opin. Biotechnol. 17 1-7
36. Toffoli G, Bevilacqua C, Franceschin A and Boiocchi M 1989 Effect of hyperthermia on intracellular drug accumulation and chemosensitivity in drug-sensitive and drug-resistant P388 leukaemia cell lines Int. J. Hyperthermia. 5 163-72
37. Trapp S and Horobin R W 2005 A predictive model for the selective accumulation of chemicals in tumor cells Eur. Biophys. J. 34 959-66
38. Wallner K E and Li G C 1987 Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin Cancer Res 47 493-5
39. Wang D and Lippard S J 2005 Cellular processing of platinum anticancer drugs Nat. Rev. Drug. Discov. 4 307-20
40. Xu P, Van Kirk E A, Li S, Murdoch W J, Ren J, Hussain M D, Radosz M and Shen Y 2006 Highly stable core-surface-crosslinked nanoparticles as cisplatin carriers for cancer chemotherapy Colloids Surf. B 48 50-7
41. Xu R 1997 Improvements in particle size analysis using light scattering Particle and Surface Characterizing Methods ed R H Müller and W Mehnert (Stuttgart: Medpharm Scientific Publisher)
42. Yang J, Park S B, Yoon H G, Huh Y M and Haam S 2006 Preparation of poly epsilon-caprolactone nanoparticles containing magnetite for magnetic drug carrier Int. J. Pharm. 324 185-90
43. Zieske P A, Koberda M, Hines J L, Knight C C, Sriram R, Raghavan N V and Rabinow B E 1991 Characterization of cisplatin degradation as affected by pH and light Am. J. Hosp. Pharm. 48 1500-6